Table 2.
Risk factors for switching to LPV/r in the cohort at multivariate analysis.
| Variables | Bivariate Analysis OR (95% CI) | p-value | Multivariate Analysis OR (95% CI) | p-value |
|---|---|---|---|---|
| Age | 0.99 (0.93–1.05) | 0.789 | ||
| Sex | ||||
| Male | 1 | 1.000 | ||
| Female | 1.00 (0.32–3.13) | |||
| Marital status | ||||
| Single | 1 | 0.895 | ||
| Married | 3.00 (0.28–32.75) | |||
| Widow/widower | 0.99 (0.29–2.87) | |||
| Occupation | ||||
| Not working | 1 | 0.353 | ||
| Steady work | 1.80 (0.52–6.22) | |||
| CD4 count | 0.99 (0.98–1.00) | 0.084 | ||
| HIV clinical stage | 2.16 (1.07–4.36) | 0.032a | ||
| Presence of Tuberculosis | ||||
| No | 1 | 0.029a | 1 | 0.007a |
| Yes | 11.11 (1.27–96.86) | 26.60 (2.41–293.81) | ||
| Tuberculosis plus other comorbidities | ||||
| No | 1 | omitted | ||
| Yes | 1 | |||
| NNRTI as the first-line drug | ||||
| Efavirenz | 1 | 0.054a | 1 | 0.011a |
| Nevirapine | 3.07 (0.98–9.59)a | 6.66 (1.56–28.45) | ||
| Cotrimoxazole prophylaxis | ||||
| No | 1 | 0.024a | ||
| Yes | 4.19 (1.21–14.54) | |||
| Adherence before switching | ||||
| Adhere Not adhere |
1 1.01 (0.99–1.03) |
0.168 | ||
a
Threshold p-value<0.25 **significant at p-value <0.05.